Latest News & Features
Europe
Non-profit alleges that Humira pricing displaced essential healthcare, violated EU competition law and breached human rights | Court notes ‘social significance’ of case—but this can’t translate into ‘legal standing’. 18 July 2025
Americas
Experts from Dechert, BlueRock Therapeutics, Merck, Seaport Therapeutics, and Ventus Therapeutics examine the impact of recent court rulings following Amgen v. Sanofi on broad genus claims within life sciences patents, as discussed at LSPN. 18 July 2025
Europe
Pharma giant can’t stop generics from unveiling copies of flagship product | Lord Justice Arnold upholds UK findings of lack of inventive step and insufficiency. 17 July 2025
Careers
Three of the new shareholders have IP and life sciences expertise, bringing a commercial and policy focus to the firm. 17 July 2025
Americas
Pharma giant wins preliminary injunction ‘in public interest’ regarding a generic of its Selenious Acid Injection | Judge finds infringement by pharma company Eugia of two Orange Book patents. 16 July 2025
Americas
LSPN experts from Goodwin Law, Invivyd, and New England Biolabs discuss the challenges of patent eligibility under 35 U.S.C. § 101 in life sciences innovation. The session explores strategies to address obstacles arising from recent court decisions and USPTO guidelines. 16 July 2025
Europe
After almost 30 years as head of IP at Bayer, Jörg Thomaier is to retire and is handing the baton to Dorian Immler. Speaking to Sarah Speight, the pair explain what makes a good IP strategy, why the UPC is largely “useless” without SPCs, and more. 15 July 2025
Africa
Africa’s agricultural future is imperative to life and prosperity in the region—and the Arusha Protocol gives breeders the protection they need, explains the African Regional Intellectual Property Organization. 15 July 2025
Americas
Janssen filed patent infringement suits in New Jersey and Delaware over proposed copy of blockbuster drug Invega Sustenna | Lawsuits follow appeals court win for J&J in separate action with Teva and Mylan. 15 July 2025
Americas
This LSPN panel features experts from Maiwald, Regeneron, Vertex Pharmaceuticals, and Taylor Wessing discussing the impact of increased transparency requirements in clinical trials and their effects on the global patent system. The session focuses on recent regulatory changes, especially in Europe, and the challenges they present for IP protection. 14 July 2025